Update of fecal markers of inflammation in inflammatory bowel disease

Thomas A. Judd, Andrew S. Day, Daniel A. Lemberg, Dan Turner, Steven T. Leach*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

75 Scopus citations

Abstract

The diagnosis, prognosis, and assessment of disease activity of inflammatory bowel disease (IBD) require investigating clinical, radiological, and histological criteria, as well as serum inflammatory markers. However, a range of fecal inflammatory markers now appears to have the potential to greatly assist in these processes. Calprotectin, a prominent neutrophil protein, was identified two decades ago as a potentially revolutionary marker for IBD. Following this discovery, numerous additional markers, including S100A12, lactoferrin, and M2-pyruvate kinase, have also been suggested as novel markers of IBD. In the present study, we provide an up-to-date review of fecal markers of IBD, and further, provide a novel analysis of each of these fecal markers in severe ulcerative colitis and compare their expression pattern in contrast to calprotectin.

Original languageAmerican English
Pages (from-to)1493-1499
Number of pages7
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume26
Issue number10
DOIs
StatePublished - Oct 2011
Externally publishedYes

Keywords

  • Calprotectin
  • Fecal marker
  • Inflammatory bowel disease
  • Lactoferrin
  • M2-pyruvate kinase
  • S100A12

Fingerprint

Dive into the research topics of 'Update of fecal markers of inflammation in inflammatory bowel disease'. Together they form a unique fingerprint.

Cite this